Neuland Laboratories Ltd
Neuland Laboratories Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Neuland targets an 18% to 20% CAGR growth over a 5-year horizon, considered aspirational by management. Neuland targets an 18% to 20% CAGR over a 5-year horizon, described as aspirational rather than linear growth (Saharsh Davuluri, page 15).
From Neuland Laboratories Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Neuland targets an 18% to 20% CAGR growth over a 5-year horizon, considered aspirational by management.
- FY26 revenue reached INR 2,000 crores, up from INR 1,500+ crores in FY24, reflecting meaningful growth after a volatile FY25.
- Growth is expected to remain lumpy and volatile in the short to medium term due to the nature of the business and newer high-value molecules.
- Long-term growth is anchored by commercial and near-commercial molecules, with a strong pipeline and increasing engagement with big pharma.
- Investments in large-scale peptide commercial facilities and an upgraded R&D center aim to expand capacity and technical capabilities, supporting sustainable growth.
- The company focuses on selective, high-quality growth opportunities even if it means short-term lumpiness.
- Management advises evaluating growth over multiple quarters (10-12 quarters) rather than quarterly precision due to inherent variability.
Profitability & Margins
See what Neuland Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Neuland is in a phase of longer capital deployment cycles focused on long-term growth rather than tactical investments (Page 11).
- Capex outflow for FY26 was INR 397.1 crores, executed with discipline aligned with strategic priorities emphasizing returns and capability building (Page 4).
- Investments include building a large-scale peptide commercial facility to expand capabilities in peptide APIs and fragments (Page 5).
- New R&D center for supporting complex programs, enhancing scientific depth, collaboration, and scale from early development to commercialization (Page 5).
- Capital allocation mindset is evolving to support larger annual capex (hundreds to INR 1,000 crores) for scaling production and engaging big pharma clients (Page 11).
- Focus on execution discipline to ensure capex translates into clear milestones and business outcomes (Page 4).
- Capital investment also supports strengthening the CDMO business and readiness for new client engagement (Page 15).
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Neuland Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not explicitly mention the exact current or expected order book or pending orders in quantitative terms.
- Management indicates "visibility for projects" especially for the new peptide facility expected to be operational by July, suggesting a healthy pipeline.
- Early-stage projects for the peptide facility are near commercial, with project visibility but not yet firm contracts.
- The business development focus is on attracting high-quality, sustainable growth opportunities and larger projects.
- CDMO business discussions emphasize ongoing engagements and contracted relationships but maintain confidentiality regarding specific molecules and orders.
- Overall, the company shows confidence in its pipeline and order visibility, particularly from commercial and near-commercial molecules, supporting growth in the next 2-3 years.
Neuland Laboratories Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹776 Cr, net profit ₹213 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Neuland Laboratories Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Torrent Pharmaceuticals Ltd (Q4 FY26)
Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…
- Kwality Pharmaceuticals Ltd (Q4 FY26)
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…
- RPG Life Sciences Ltd (Q4 FY26)
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…
- Sai Parenterals Ltd (Q4 FY26)
Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…
Frequently Asked Questions
What were Neuland Laboratories Ltd Q4 FY26 results?
Neuland targets an 18% to 20% CAGR growth over a 5-year horizon, considered aspirational by management. Neuland targets an 18% to 20% CAGR over a 5-year horizon, described as aspirational rather than linear growth (Saharsh Davuluri, page 15).
What is Neuland Laboratories Ltd share price analysis?
Neuland Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 51.4 with a market cap of ₹25,603 Cr. Investors should review the full earnings analysis for detailed insights.
Is Neuland Laboratories Ltd planning capital expenditure?
Neuland is in a phase of longer capital deployment cycles focused on long-term growth rather than tactical investments (Page 11).
Keep Neuland Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.